AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18940487
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of methocarbamol (380 mg) and paracetamol (300 mg) every 6 hours for 4 weeks
Trial: 647173
Drug: Hypnotic induction
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic induction procedure
Trial: 12585146
Drug: Yufeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yufeng Capsule (YFC)
Trial: 1540431
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for heparin
Trial: 3536765
Drug: RU 41740
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 41740 (Biostim®) 8 mg daily for 14 days
Trial: 27783545
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to Patient Drug Adherence Information (PDAI)
Trial: 25900517
Drug: FDC (FF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC (FF 100 μg/LEVO 200 μg)
Trial: 21042763
Drug: 180 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg/m2 irinotecan with 5-FU/leucovorin
Trial: 14740952
Drug: Monovalent live
RxNorm normalized name: INFLUENZA A (H1N1) MONOVALENT LIVE VACCINE,NASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent live attenuated dengue virus vaccine candidates
Trial: 14740952
Drug: Monovalent vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent vaccines (second dose at 30 or 90 days)
Trial: 14740952
Drug: Tetravalent vaccine
RxNorm normalized name: DENGUE TETRAVALENT VACCINE,LIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent vaccine (single dose)
Trial: 14740952
Drug: Tetravalent vaccine
RxNorm normalized name: DENGUE TETRAVALENT VACCINE,LIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent vaccine (second dose at one month)
Trial: 30958356
Drug: ω3‐FA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω3‐FA supplementation (1.7g docosahexaenoic acid and 0.6g eicosapentaenoic acid daily for 6 months)
Trial: 27870826
Drug: rhIGF‐1/rhIGFBP‐3, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF‐1/rhIGFBP‐3, administered at 250 µg/kg/d continuous i.v. infusion up to postmenstrual age 29 wk+6 d
Trial: 9848295
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of luteal phase support in women with serum progesterone levels of < 60 ng/mL at 4 weeks' gestation
Trial: 21813090
Drug: 0.59‐mg fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.59‐mg fluocinolone acetonide (FA) implant
Trial: 15258869
Drug: 0.075 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075 mg/kg intravenous morphine sulfate
Trial: 11705788
Drug: OCP (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCP (oral contraceptives containing progesterone)
Trial: 11705788
Drug: OCEP (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCEP (oral contraceptives containing progesterone and estrogen)
Trial: 3050188
Drug: Ceftizoxime (CZX)
DrugBank: Ceftizoxime (DB01332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (CZX) in various dosing regimens
Trial: 31782193
Drug: Nasal Spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal Spray (NS)
Trial: 31782193
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) kit
Trial: 27243353
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution (0.9% NaCl)
Trial: 14751924
Drug: Standard-timing induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-timing induction therapy
Trial: 10195532
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg meperidine
Trial: 10195532
Drug: 1.8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg/kg meperidine
Trial: 2405108
Drug: rIL-2 via
RxNorm normalized name: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34)-peptide of parathyroid hormone (Homo sapiens parath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIL-2 via splenic artery infusion
Trial: 25301760
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (long-term androgen deprivation therapy - ADT)
Trial: 15380045
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT), calcium, and vitamin D3
Trial: 8217756
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied once daily for 40 weeks
Trial: 3296861
Drug: Anticoagulants (phenprocoumon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (phenprocoumon or acenocoumarol)
Trial: 3296861
Drug: Anticoagulants (phenprocoumon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (phenprocoumon or acenocoumarol) plus pentoxifylline (800-1200 mg/day)
Trial: 3296861
Drug: Irregular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irregular treatment with various vasodilators (xanthinolnicotinate, naftidrofuryl, pyridylmethanol, etc.)
Trial: 26708108
Drug: Placebo CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo CBD (0 mg)
Trial: 26708108
Drug: CBD (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (800 mg)
Trial: 19920426
Drug: Ultrasound-guided interscalene
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Trial: 19920426
Drug: Nerve stimulation
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve stimulation interscalene brachial plexus block with 10 mL of ropivacaine 0.75%
Trial: 10943872
Drug: Leflunomide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (20 mg/day after a 3-day 100 mg/day loading dose)
Trial: 8330603
Drug: Propofol 2.79
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.79 +/- 0.4 mg kg‐1 h‐1
Trial: 8330603
Drug: Midazolam 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.08 +/- 0.01 mg kg‐1 h‐1
Trial: 8330603
Drug: Methohexitone 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone 1.8 +/- 0.2 mg kg‐1 h‐1
Trial: 8330603
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sedative agent)
Trial: 3275752
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CMF) with endocrine treatment (prednisone, oophorectomy)
Trial: 7004624
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (CMF)
Trial: 29401246
Drug: Lifastuzumab vedotin
RxNorm normalized name: Lifastuzumab vedotin
DrugBank: Lifastuzumab vedotin (DB15400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifastuzumab vedotin (LIFA) 2.4 mg/kg, intravenously, every 3 weeks (Q3W)
Trial: 29401246
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m2, intravenously, every 4 weeks (Q4W)
Trial: 25306088
Drug: Oral olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral olive oil
Trial: 25306088
Drug: Oral sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sunflower oil (control)
Trial: 9885327
Drug: Calcium carbasalate
RxNorm normalized name: carbasalate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbasalate (equivalent to 900 mg aspirin) plus metoclopramide 10 mg (CM)
Trial: 9885327
Drug: Ergotamine tartrate
RxNorm normalized name: Ergotamine Tartrate
DrugBank: Ergotamine (DB00696)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergotamine tartrate 1 mg plus caffeine 100 mg (EC)
Trial: 7102707
Drug: 3 percent
RxNorm normalized name: SALICYLIC ACID 3 g in 100 g TOPICAL GEL [Keralyt 3 PERCENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 percent acyclovir ointment
Trial: 29139301
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 or 25 mg/day)
Trial: 3519644
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg/day)
Trial: 15499953
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml 30% glucose by syringe
Trial: 24649762
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) as monotherapy, performed 1 time per week for 4 weeks.
Trial: 24649762
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (control group).
Trial: 11052952
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) with endurance training
Trial: 6329863
Drug: Cereal-fibre-rich diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cereal-fibre-rich diet (42.4 g dietary fibre/6.7 MJ)
Trial: 6329863
Drug: Diabetic diet
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic diet (18.9 g dietary fibre/6.7 MJ)
Trial: 27327855
Drug: Minimal-dose S-ketamine
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal-dose S-ketamine (0.015 mg/kg/h infusion following a saline bolus)
Trial: 25003802
Drug: Treatment 4
RxNorm normalized name: Acne Treatment 4 % - 5 % Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 4 (transportation, screening, and prenatal, postpartum, and infant/toddler home visiting)
Trial: 25003802
Drug: Combined control
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined control group (treatments 1 and 2)
Trial: 25003802
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 (transportation plus developmental screening for infants and toddlers)
Trial: 22775763
Drug: Antiplatelet agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agent use
Trial: 19574331
Drug: INTERCOM programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTERCOM programme (exercise training, education, nutritional therapy, smoking cessation counselling)
Trial: 16343856
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg
Trial: 20977368
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg
Trial: 8562105
Drug: Propafenone (38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (38 patients: 2 mg/kg over 15 min and then 10 mg/kg over the subsequent 24 h for non-converting)
Trial: 602958
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of sisomicin
Trial: 602958
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of sisomicin
Trial: 28531467
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine consumption (once daily for 1 month)
Trial: 20520568
Drug: Fixed-combination latanoprost/timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-combination latanoprost/timolol (Xalacom)
Trial: 7970848
Drug: Fluoroquinolone therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone therapy
Trial: 9776797
Drug: Self-monitoring tool
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-monitoring tool with monthly feedback of phosphorus levels and interdialytic weight gains
Trial: 3043077
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange with corticosteroids, cytotoxic drug, hemodialysis only when needed (Group I)
Trial: 7402084
Drug: Nordiol (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nordiol (combination of ethinyl oestradiol and norgestrel)
Trial: 30241872
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who did not receive information about their medications
Trial: 30241872
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who integrated medication dosing into daily routines
Trial: 27231800
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation (intervention group)
Trial: 25093754
Drug: Daily trimethoprim‐sulfamethoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily trimethoprim‐sulfamethoxazole (TS)
Trial: 20574541
Drug: Monthly sulfadoxine‐pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulfadoxine‐pyrimethamine (SP)
Trial: 19068274
Drug: Intermittent FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent FOLFIRI chemotherapy
Trial: 19068274
Drug: Continuous FOLFIRI
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous FOLFIRI chemotherapy
Trial: 9835004
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (mean 5.2 x 10(6) KIU)
Trial: 9835004
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (2 x 10(6) KIU)
Trial: 9835004
Drug: Aprotinin-treated patients
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin-treated patients (both doses)
Trial: 2521409
Drug: Orthoclone OKT3
RxNorm normalized name: Orthoclone OKT3
DrugBank: Muromonab (DB00075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthoclone OKT3 for 14 days, azathioprine, and steroids
Trial: 1080382
Drug: Phenylbutazone-prednisone combination
RxNorm normalized name: Phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylbutazone-prednisone combination
Trial: 29911777
Drug: Herbal Extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal Extract Cream
Trial: 25785703
Drug: 6% Carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% Carbohydrate (CHO) solution (15 g; 0.20 ± 0.02 g·kg(‐1))
Trial: 25785703
Drug: 1.2% Caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% Caffeine (CAF) solution (300 mg; 3.9 ± 0.3 mg·kg(‐1))
Trial: 25785703
Drug: Carbohydrate with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate with caffeine (C + C) solution
Trial: 23480456
Drug: M (PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M (PCA regimen with morphine)
Trial: 23480456
Drug: TM (PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TM (PCA regimen with tenoxicam and morphine)
Trial: 23480456
Drug: T+TM (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+TM (20 mg tenoxicam administered 30 minutes before wound closure in addition to the TM regimen)
Trial: 10688810
Drug: Cs‐A3 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cs‐A3 (3 mg/kg/d)
Trial: 10688810
Drug: Cs‐A1 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cs‐A1 (1 mg/kg/d)
Trial: 1353088
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (untreated with topical antiseptics)
Trial: 3922070
Drug: 20 per
RxNorm normalized name: evolocumab 420 per 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 per cent lipid solution
Trial: 3922070
Drug: Fat solutions
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat solutions alone or in combination with isotonic concentrations of dextrose
Trial: 24114693
Drug: Fixed-time schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-time schedule of brief breaks (noncontingent escape) from ongoing dental treatment
Trial: 15947609
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for 28 days
Trial: 8723848
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg, administered intramuscularly 30 minutes before surgery
Trial: 8723848
Drug: Saline (placebo),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (placebo), administered intramuscularly 30 minutes before surgery
Trial: 23622906
Drug: BioFreedom drug-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BioFreedom drug-coated stent
Trial: 9727544
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg once daily)
Trial: 23625113
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg once daily)
Trial: 3300755
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo followed at 35 min by i.v. diazepam 10 mg (Diazemuls)
Trial: 30371148
Drug: MDMA 40
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 40 mg (low dose)
Trial: 24970869
Drug: Paricalcitol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (1 μg/d)
Trial: 29880356
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 μg/d)
Trial: 24363547
Drug: Cotrimoxazole Prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole Prophylactic Treatment (CPT)
Trial: 15735111
Drug: Daily multiple
RxNorm normalized name: Daily Multiple Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multiple micronutrient (DMM) supplementation
Trial: 15735111
Drug: Weekly multiple
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly multiple micronutrient (WMM) supplementation
Trial: 15735111
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron (DI) supplementation
Trial: 12057733
Drug: GnRHa (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa (3.75 mg/4 weeks of triptorelin or 3.6 mg/4 weeks of goserelin)
Trial: 15716202
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg po qhs for at least 4 weeks
Trial: 11834123
Drug: High-dose glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glutamine (0.3 g x kg(‐1))
Trial: 11834123
Drug: Glycine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine (0.3 g x kg(‐1))
Trial: 7720759
Drug: felodipine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine (any dose)
Trial: 7720759
Drug: HCTZ (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ (any dose)
Trial: 30116855
Drug: Non-opioid medications
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid medications (e.g., paracetamol, metamizole)
Trial: 22183173
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg with moderate-fat meal
Trial: 22183173
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg with high-fat meal
Trial: 11122795
Drug: Primary therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary therapy
Trial: 11122795
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with autologous hematopoietic support
Trial: 8800784
Drug: Micronized 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized 17 beta‐oestradiol (2 mg/day) continuously with dydrogesterone (10 mg/day) for the first 14 days of each cycle
Trial: 31048187
Drug: Hydrocolloid dressings
RxNorm normalized name: Restore Extra Thin Hydrocolloid Dressings, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid dressings (VARIHESIVE® GEL CONTROL)
Trial: 23161301
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a (40KD; 180 μg/week)